Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134425 | 0.96 | CA12 (0.40) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL4439958 | 0.84 | CA12 (0.44) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL4439952 | 0.83 | CA12 (0.43) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL4149554 | 0.82 | IDO1 (0.47) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL4140584 | 0.82 | CA12 (0.43) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL4335153 | 0.80 | CA12 (0.44) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL4135777 | 0.79 | HSD11B1 (0.33) | — | |
| SCHEMBL4335148 | 0.79 | CA12 (0.43) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL2767190 | 0.73 | ALDH1A1 (0.45) | — | |
| SCHEMBL21632365 | 0.70 | CA1 (0.53) | CA12CA1CA2CA9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | CA12 4795/4885CA1 4662/4885CA2 3687/4885 |
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | CA12 2476/4885CA1 4162/4885CA2 2149/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | CA12 4783/4885CA1 4811/4885CA2 3786/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | CA12 2814/4885CA1 3956/4885CA2 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.